Because studies have shown that cancer cell stemness may be enhanced by treatment with a low concentration of cisplatin34–36, we treated the second set of selected CD326+, CD117+, or CD117+/CD326+ cells derived from CD326+ cells with cisplatin at concentrations of 0.64, 3.2, and 16 μM and found that the number of CD326+ cells was highly increased by cisplatin treatment (Fig. 7f and Supplementary Fig. 14m). The gene discussed is EPCAM; the disease is cancer.